Cantor Fitzgerald Initiates Coverage On Milestone Pharmaceuticals with Overweight Rating, Announces Price Target of $3

Milestone Pharmaceuticals Presenting Data In Moderated EPoster Session Titled 'he Impact of PSVT on Patients’ Daily Life and QoL in Between Episodes' At European Society Of Cardiology Congress 2026

Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced findings from a longitudinal study

Milestone Pharmaceuticals Announces First Patient Enrolled In Phase 3 Trial Of Etripamil In Approximately 150 Patients With Atrial Fibrillation With Rapid Ventricular Rate

This Sphere Entertainment Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday

Top Wall Street analysts updated ratings on SPHR, CVLG, MIST, MSGE,. Check out analyst ratings page for full details and stock recommendations.